A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT03091257
Phase
PHASE1
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This research study is studying a targeted therapy as a possible treatment for multiple myeloma. The names of the study drugs involved in this study are: * Trametinib * Dabrafenib

Key Dates

Start date
Jun 21, 2017
Status verified
Mar 2026
Primary completion
Jul 15, 2026
Completion
Sep 15, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Dabrafenib
    Determine if mutation in BRAF, KRAS, NRAS * BRAF V600 mutated * Treat cohort with Dabrafenib * Analysis * Treat cohort with Dabrafenib
  • Experimental: Dabrafenib and Trametinib
    Determine if mutation in BRAF, KRAS, NRAS * BRAF V600 mutated, BRAF/KRAS mutated, or BRAF/NRAS mutated, or BRAF non-V600 mutated * Treat cohort with Dabrafenib and Trametinib * Analysis * Treat cohort with Dabrafenib and Trametinib
  • Experimental: Trametinib
    Determine if mutation in BRAF, KRAS, NRAS * KRAS or NRAS mutated * Treat cohort with Trametinib * Analysis * Treat cohort with Trametinib

Primary Outcome Measure

Overall Response Rate [ Time Frame: 100 weeks ]

Locations (2)

FacilityCityStateZIPSite coordinators
Massachusetts General HospitalBostonMassachusetts02115-
Karmanos Cancer InstituteDetroitMichigan48201-

Find similar trials in Boston, MA

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Massachusetts General Hospital· Boston, MAKarmanos Cancer Institute· Detroit, MI

Related Studies